Asahi Intecc (7747) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Feb, 2026Executive summary
Net sales for the first half of FY2026 reached ¥71,266 million, up 15.9% year-over-year, driven by strong demand in both Medical and Device Divisions.
Operating profit rose 40.1% to ¥24,372 million, with ordinary profit up 43.5% to ¥24,143 million and net income attributable to shareholders up 40.4% to ¥17,214 million.
Gross profit margin improved from 67.6% to 70.6% due to productivity gains, and extraordinary income rose from gains on sale of investment securities.
Financial highlights
Gross profit grew 21.1% year-over-year to ¥50,311 million.
EPS increased 43.0% to ¥64.56.
SGA expenses rose 7.4% year-over-year, mainly from increased sales promotion and R&D.
Comprehensive income nearly doubled year-over-year to ¥24,378 million.
Net assets rose to ¥158,671 million, with an equity-to-asset ratio of 80.6%.
Outlook and guidance
Full-year forecast for FY ending June 30, 2026, was revised upward: net sales expected at ¥141,142 million (+17.6%), operating profit at ¥42,220 million (+40.4%), and profit attributable to owners of parent at ¥30,556 million (+139.9%).
Dividend forecast for FY ending June 30, 2026, raised to ¥46.10 per share, including a ¥5.79 commemorative dividend.
Latest events from Asahi Intecc
- Raising 2030 targets, the plan accelerates global growth in high value-added medical devices.7747
Corporate presentation - Strong sales and profit growth driven by Medical and Device divisions and overseas demand.7747
Q4 2026 - Operating profit up 45.5% and net income up 204.2% year-over-year, with strong outlook.7747
Q3 2026 - Strong sales and profit growth, with improved margins and some European market uncertainty.7747
Q1 2026 - Strong sales and profit growth led by Medical, but net income declined on impairment losses.7747
Q4 2025 - Medical Division growth and margin gains drove strong profit increases; outlook steady.7747
Q1 2025 - Record revenue and profit growth, with strong Medical Division performance and robust outlook.7747
Q4 2024 - Strong sales and operating profit growth offset by major impairment losses.7747
Q3 2025 - Medical Division growth and margin gains drove strong profit and positive outlook.7747
Q2 2025